We compared the efficacy and safety of three doses of recombinant GLP-@ , ranging from @ to @ pmol/kg/min ( pkm ) and placebo , given by continuous subcutaneous infusion over @months in combination with metformin and sulphonylurea ( SU ) , to lower haemoglobin A@c ( HbA@c ) , fasting plasma glucose and weight in @ type @ diabetes patients with inadequate glycaemic control .